A Multicenter, Randomized, Parallel-Group Trial Assessing Compliance, Tolerability, Safety, and Efficacy to Treatment with Grass Allergy Tablets in 261 Patients with Grass Pollen Rhinoconjunctivitis

Table 1

Patients demographic characteristics at baseline.

Treatment Group	Grazax+; Memozax	Grazax−; Memozax
Number of subjects	139	122
Age (years) #
N	139	122
Mean (SD)	32 (9)	33 (10)
Median	32.0	33.0
Min-Max	19–60	18–63
Sex
N	139	22
Men	75 (54%)	74 (60%)
Women	64 (46%)	48 (40%)
Allergic rhinitis
Mild	37 (26%)	33 (27%)
Moderate/severe	102 (74%)	89 (73%)
Monosensitive subjects	32 (23%)	36 (29%)
Polysensitive subjects	107 (77%)	86 (71%)
Asthma (Gina class: I–III)
N	25 (18%)	25 (20%)

N: Number of subjects; (%): Percent of subjects.